HS
AXSM icon

HighVista Strategies’s Axsome Therapeutics AXSM Stock Holding History

HighVista Strategies’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.45M Buy
20,437
+9,306
+84% +$1.61M 0.95% 32
2025
Q4 		$2.03M Buy
11,131
+1,783
+19% +$249K 0.52% 51
2025
Q3 		$1.14M Sell
9,348
-1,561
-14% -$176K 0.28% 113
2025
Q2 		$1.14M Sell
10,909
-10,594
-49% -$1.12M 0.42% 101
2025
Q1 		$2.51M Buy
21,503
+4,379
+26% +$499K 0.97% 19
2024
Q4 		$1.45M Sell
17,124
-24,418
-59% -$2.25M 0.54% 74
2024
Q3 		$3.73M Sell
41,542
-20,650
-33% -$1.8M 1.29% 17
2024
Q2 		$5.01M Buy
62,192
+13,665
+28% +$1.01M 1.83% 5
2024
Q1 		$3.87M Sell
48,527
-13,736
-22% -$1.15M 1.38% 17
2023
Q4 		$4.96M Buy
62,263
+5,299
+9% +$354K 1.8% 5
2023
Q3 		$3.98M Buy
56,964
+7,564
+15% +$565K 1.84% 10
2023
Q2 		$3.55M Sell
49,400
-11,374
-19% -$839K 1.62% 12
2023
Q1 		$3.75M Buy
60,774
+5,650
+10% +$371K 3.05% 4
2022
Q4 		$4.25M Buy
55,124
+38,238
+226% +$2.29M 2.52% 6
2022
Q3 		$753K Buy
+16,886
New +$844K 0.43% 63
2021
Q2 		– Sell
-11,664
Closed -$660K – 124
2021
Q1 		$660K Buy
11,664
+651
+6% +$45.8K 0.49% 47
2020
Q4 		$897K Buy
11,013
+5,001
+83% +$374K 0.57% 36
2020
Q3 		$428K Sell
6,012
-929
-13% -$72.4K 0.31% 63
2020
Q2 		$571K Buy
+6,941
New +$534K 0.47% 15

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighVista Strategies's AXSM Position: Q1 2026 in Review

HighVista Strategies increased its Axsome Therapeutics (AXSM) stake by 84% in Q1 2026, buying an estimated $1.61M and bringing the position to 20,437 shares worth $3.45M. The position accounts for 0.95% of the portfolio, ranked #32.

HighVista Strategies first reported a position in AXSM in Q2 2020 and has held it in 19 quarters since. The position peaked at $5.01M in Q2 2024. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • HighVista Strategies held 20,437 shares of Axsome Therapeutics worth $3.45M as of Q1 2026.
  • HighVista Strategies bought 9,306 Axsome Therapeutics shares in Q1 2026, an estimated $1.61M.
  • Axsome Therapeutics made up 0.95% of HighVista Strategies's portfolio in Q1 2026, its #32 holding.
  • HighVista Strategies first reported a position in Axsome Therapeutics in Q2 2020 and has held it in 19 quarters since.
  • HighVista Strategies's Axsome Therapeutics position peaked at $5.01M in Q2 2024.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.